An International, Phase 3, Randomized, Multicenter, Openlabel Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT)

PI: Elena Rosa Fumagalli

This is a study comparing Ripretinib -a conventional fourth-line drug- with sunitinib -a conventional second-line drug- in a specific population of patients with GIST, characterized by a primary mutation affecting exon 11 of the KIT gene and secondary mutations (which cause resistance to imatinib), affecting exons 17 and 18 of the same gene.